tetano
Editor, Senior Moderator
Front Immunol
. 2021 Nov 18;12:778829.
doi: 10.3389/fimmu.2021.778829. eCollection 2021.
MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants
Sua Lee[SUP] 1 [/SUP], Shina Jang[SUP] 1 [/SUP], Jihoon Kang[SUP] 1 [/SUP], Soo Bin Park[SUP] 1 [/SUP], Young Woo Han[SUP] 2 [/SUP], Hyemi Nam[SUP] 3 [/SUP], Munkyung Kim[SUP] 3 [/SUP], Jeewon Lee[SUP] 3 [/SUP], Ki Joon Cho[SUP] 1 [/SUP], Jeonghun Kim[SUP] 4 [/SUP], Miyoung Oh[SUP] 1 [/SUP], Jihye Ryu[SUP] 5 [/SUP], Jong Hyeon Seok[SUP] 4 [/SUP], Yunhwa Kim[SUP] 6 [/SUP], Jee-Boong Lee[SUP] 3 [/SUP], Man-Seong Park[SUP] 4 [/SUP], Yong-Sung Kim[SUP] 7 [/SUP], Hosun Park[SUP] 6 [/SUP], Dong-Sik Kim[SUP] 1 7 [/SUP]
Affiliations
Abstract
Since the coronavirus disease outbreak in 2019, several antibody therapeutics have been developed to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Antibody therapeutics are effective in neutralizing the virus and reducing hospitalization in patients with mild and moderate infections. These therapeutics target the spike protein of SARS-CoV-2; however, emerging mutations in this protein reduce their efficiency. In this study, we developed a universal SARS-CoV-2 neutralizing antibody. We generated a humanized monoclonal antibody, MG1141A, against the receptor-binding domain of the spike protein through traditional mouse immunization. We confirmed that MG1141A could effectively neutralize live viruses, with an EC[SUB]50[/SUB] of 92 pM, and that it exhibited effective Fc-mediated functions. Additionally, it retained its neutralizing activity against the alpha (UK), beta (South Africa), and gamma (Brazil) variants of SARS-CoV-2. Taken together, our study contributes to the development of a novel antibody therapeutic approach, which can effectively combat emerging SARS-CoV-2 mutations.
Keywords: MG1141A; SARS-CoV-2; monoclonal antibody; outbreak; spike protein.
. 2021 Nov 18;12:778829.
doi: 10.3389/fimmu.2021.778829. eCollection 2021.
MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants
Sua Lee[SUP] 1 [/SUP], Shina Jang[SUP] 1 [/SUP], Jihoon Kang[SUP] 1 [/SUP], Soo Bin Park[SUP] 1 [/SUP], Young Woo Han[SUP] 2 [/SUP], Hyemi Nam[SUP] 3 [/SUP], Munkyung Kim[SUP] 3 [/SUP], Jeewon Lee[SUP] 3 [/SUP], Ki Joon Cho[SUP] 1 [/SUP], Jeonghun Kim[SUP] 4 [/SUP], Miyoung Oh[SUP] 1 [/SUP], Jihye Ryu[SUP] 5 [/SUP], Jong Hyeon Seok[SUP] 4 [/SUP], Yunhwa Kim[SUP] 6 [/SUP], Jee-Boong Lee[SUP] 3 [/SUP], Man-Seong Park[SUP] 4 [/SUP], Yong-Sung Kim[SUP] 7 [/SUP], Hosun Park[SUP] 6 [/SUP], Dong-Sik Kim[SUP] 1 7 [/SUP]
Affiliations
- PMID: 34868052
- PMCID: PMC8637776
- DOI: 10.3389/fimmu.2021.778829
Abstract
Since the coronavirus disease outbreak in 2019, several antibody therapeutics have been developed to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Antibody therapeutics are effective in neutralizing the virus and reducing hospitalization in patients with mild and moderate infections. These therapeutics target the spike protein of SARS-CoV-2; however, emerging mutations in this protein reduce their efficiency. In this study, we developed a universal SARS-CoV-2 neutralizing antibody. We generated a humanized monoclonal antibody, MG1141A, against the receptor-binding domain of the spike protein through traditional mouse immunization. We confirmed that MG1141A could effectively neutralize live viruses, with an EC[SUB]50[/SUB] of 92 pM, and that it exhibited effective Fc-mediated functions. Additionally, it retained its neutralizing activity against the alpha (UK), beta (South Africa), and gamma (Brazil) variants of SARS-CoV-2. Taken together, our study contributes to the development of a novel antibody therapeutic approach, which can effectively combat emerging SARS-CoV-2 mutations.
Keywords: MG1141A; SARS-CoV-2; monoclonal antibody; outbreak; spike protein.